All In Biotech

Drug Trial Radar · NCT07760818

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Oct 9, 2026

Primary completion

Jul 28, 2028

Study completion Jul 28, 2029

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Conditions

  • Sjogrens Disease
  • Primary Sjögren's Syndrome Painful Sensory Neuropathies

Interventions

  • efgartigimod PH20 SCBiological

    subcutaneous efgartigimod PH20 SC given by prefilled syringe

  • Placebo PH20 SCOther

    subcutaneous placebo PH20 SC given by prefilled syringe

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part ATime frame: Up to 48 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sarasota Arthritis Research Center

    Sarasota, Florida · Recruiting

  • Vantage Clinical Trials Tampa

    Tampa, Florida · Recruiting

  • Revive Research Institute Inc

    Sterling Heights, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.